Camurus AB Cash Flow Conversion Efficiency

Latest as of December 2025: 0.060x

Camurus AB cash flow conversion efficiency. Based on the latest financial reports, Camurus AB (CAMX) has a cash flow conversion efficiency ratio of 0.060x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr255.43 Million ≈ $27.49 Million USD) by net assets (Skr4.24 Billion ≈ $455.80 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Camurus AB (2012–2025)

Cash flow conversion efficiency of Camurus AB from 2012 to 2025. This chart illustrates how Camurus AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Camurus AB share price for real-time trading data and today's change.

Camurus AB Cash Flow Conversion Ratio Explained

Camurus AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Camurus AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Camurus AB ranked by their cash flow conversion efficiency. Also see market value of Camurus AB for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
D-Wave Quantum Inc.
NYSE:QBTS
-0.040x
Bank Handlowy w Warszawie SA
WAR:BHW
-0.309x
Flughafen Wien Aktiengesellschaft
VI:FLU
0.039x
Enova International Inc
NYSE:ENVA
0.363x
Shanghai Lujiazui Finance & Trade Zone Development Co Ltd A
SHG:600663
0.058x
Grupo Aeroportuario del Centro Norte S.A.B. de C.V.
F:G7A
0.137x
Bidvest Group Ltd
JSE:BVT
0.172x
Cinemark Holdings Inc
NYSE:CNK
0.174x

Annual Cash Flow Conversion Efficiency for Camurus AB (2012–2025)

The table below shows the annual cash flow conversion efficiency of Camurus AB from 2012 to 2025. Review Camurus AB (CAMX) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 Skr4.24 Billion
≈ $455.80 Million
Skr869.30 Million
≈ $93.55 Million
0.205x +74.02%
2024-12-31 Skr3.29 Billion
≈ $354.02 Million
Skr387.99 Million
≈ $41.75 Million
0.118x -70.98%
2023-12-31 Skr1.49 Billion
≈ $160.67 Million
Skr606.88 Million
≈ $65.31 Million
0.406x +299.53%
2022-12-31 Skr994.67 Million
≈ $107.04 Million
Skr101.20 Million
≈ $10.89 Million
0.102x +160.22%
2021-12-31 Skr848.91 Million
≈ $91.36 Million
Skr-143.43 Million
≈ $-15.44 Million
-0.169x +40.05%
2020-12-31 Skr847.44 Million
≈ $91.20 Million
Skr-238.83 Million
≈ $-25.70 Million
-0.282x +55.98%
2019-12-31 Skr631.63 Million
≈ $67.97 Million
Skr-404.36 Million
≈ $-43.52 Million
-0.640x +41.06%
2018-12-31 Skr252.32 Million
≈ $27.15 Million
Skr-274.08 Million
≈ $-29.50 Million
-1.086x -105.94%
2017-12-31 Skr385.00 Million
≈ $41.43 Million
Skr-203.07 Million
≈ $-21.85 Million
-0.527x -43.27%
2016-12-31 Skr564.42 Million
≈ $60.74 Million
Skr-207.79 Million
≈ $-22.36 Million
-0.368x -4068.62%
2015-12-31 Skr640.56 Million
≈ $68.93 Million
Skr-5.66 Million
≈ $-608.78K
-0.009x -101.57%
2014-12-31 Skr123.46 Million
≈ $13.29 Million
Skr69.43 Million
≈ $7.47 Million
0.562x -82.74%
2013-12-31 Skr50.05 Million
≈ $5.39 Million
Skr163.06 Million
≈ $17.55 Million
3.258x +429.67%
2012-12-31 Skr40.21 Million
≈ $4.33 Million
Skr24.73 Million
≈ $2.66 Million
0.615x --

About Camurus AB

ST:CAMX Sweden Biotechnology
Market Cap
$4.33 Billion
Skr40.20 Billion SEK
Market Cap Rank
#3817 Global
#56 in Sweden
Share Price
Skr674.00
Change (1 day)
+0.15%
52-Week Range
Skr437.40 - Skr704.00
All Time High
Skr733.50
About

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029… Read more